Evidence map›Paper›PMID 35453260›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Inactivation of a New Potassium Channel Increases Rifampicin Resistance and Induces Collateral Sensitivity to Hydrophilic Antibiotics in

Thi Thuy Do, Jerónimo Rodríguez-Beltran, Esmeralda Cebrián-Sastre, Alexandro Rodríguez-Rojas, Alfredo Castañeda-García, Jesús Blázquez

Abstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. c-di-AMP determines the hierarchical organization of bacterial RCK proteins.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Thi Thuy DoDepartment of Agriculture, Food and the Marine, Backweston Campus, W23 X3PH Celbridge, Ireland.
Jerónimo Rodríguez-BeltranDepartment of Microbiology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain.
Esmeralda Cebrián-SastreCentro Nacional de Biotecnología-CSIC, Darwin 3, Campus de la Universidad Autónoma de Madrid, 28049 Madrid, Spain.ORCID 0000-0002-5594-387X
Alexandro Rodríguez-RojasInternal Medicine-Vetmeduni Vienna, Veterinärplatz 1, 1210 Vienna, Austria.ORCID 0000-0002-4119-8127
Alfredo Castañeda-GarcíaCentro Nacional de Biotecnología-CSIC, Darwin 3, Campus de la Universidad Autónoma de Madrid, 28049 Madrid, Spain.
Jesús BlázquezCentro Nacional de Biotecnología-CSIC, Darwin 3, Campus de la Universidad Autónoma de Madrid, 28049 Madrid, Spain.

Funding

Instituto de Salud Carlos III CB21/13/0084Instituto de Salud Carlos III CP20/00154Instituto de Salud Carlos III FI18/00036Instituto de Salud Carlos III PI17/00159Instituto de Salud Carlos III PI21/01363MCIN/AEI/10.13039/501100011033 PID2020-112865RB-I00
6 · The paper itself

Abstract

Rifampicin is a critical first-line antibiotic for treating mycobacterial infections such as tuberculosis, one of the most serious infectious diseases worldwide. Rifampicin resistance in mycobacteria is mainly caused by mutations in the

Indexed as

collateral susceptibilityionic balanceisoniazidmycobacteriapotassium channelrifampicin resistance

Identifiers

PMID35453260
PMCPMC9025972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.